Kopion Asset Management LLC Grows Stake in Certara, Inc. $CERT

Kopion Asset Management LLC increased its position in Certara, Inc. (NASDAQ:CERT) by 11.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 655,646 shares of the company’s stock after purchasing an additional 66,756 shares during the period. Certara accounts for 5.2% of Kopion Asset Management LLC’s portfolio, making the stock its 10th biggest position. Kopion Asset Management LLC owned approximately 0.41% of Certara worth $8,012,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Northern Trust Corp grew its holdings in Certara by 4.5% in the first quarter. Northern Trust Corp now owns 916,299 shares of the company’s stock worth $9,071,000 after purchasing an additional 39,289 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of Certara in the 1st quarter worth approximately $297,000. Versor Investments LP grew its stake in shares of Certara by 104.0% in the 2nd quarter. Versor Investments LP now owns 89,346 shares of the company’s stock worth $1,045,000 after buying an additional 45,546 shares during the last quarter. Intech Investment Management LLC bought a new position in Certara during the 2nd quarter valued at approximately $329,000. Finally, Ameriprise Financial Inc. raised its stake in Certara by 13.6% during the first quarter. Ameriprise Financial Inc. now owns 4,295,566 shares of the company’s stock valued at $42,526,000 after buying an additional 515,911 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Price Performance

Shares of NASDAQ:CERT opened at $9.11 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 130.14 and a beta of 1.46. The business has a 50-day simple moving average of $9.97 and a two-hundred day simple moving average of $10.75. Certara, Inc. has a fifty-two week low of $8.02 and a fifty-two week high of $15.69.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.03. The firm had revenue of $104.62 million during the quarter, compared to analyst estimates of $104.53 million. Certara had a net margin of 2.62% and a return on equity of 5.18%. During the same period in the previous year, the business posted $0.13 earnings per share. Certara has set its FY 2025 guidance at 0.450-0.470 EPS. On average, analysts expect that Certara, Inc. will post 0.28 earnings per share for the current year.

Analyst Ratings Changes

CERT has been the topic of a number of recent research reports. KeyCorp increased their target price on Certara from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Stephens dropped their price target on shares of Certara from $15.00 to $12.00 and set an “overweight” rating on the stock in a research note on Friday, December 12th. Rothschild Redb upgraded shares of Certara to a “strong-buy” rating in a research note on Friday, November 21st. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a report on Monday, December 15th. Finally, Barclays cut their price target on shares of Certara from $14.00 to $13.00 and set an “overweight” rating on the stock in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.91.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.